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Abstract
Background: Pigmentation in human skin is an important defense mechanism against sunlight or oxidative stress.
Despite the protective role of melanin, abnormal hyperpigmentation such as freckles and chloasma sometimes can
be serious aesthetic problems. Because of these effects of hyperpigmentation, people have considered the effect of
depigmentation. Azelaic acid (AZ) is a saturated dicarboxylic acid found naturally in wheat, rye, and barley.
Previously, we showed that AZ inhibited melanogenesis. In this study, we investigated the antimelanogenic activity
of combination of AZ and taurine (Tau) in B16F10 mouse melanoma cells.
Methods: The mouse melanoma cell line B16F10 was used in the study. We measured melanin contents and
tyrosinase activity. To gain the change of protein expression, we carried out western blotting.
Results: We investigated that AZ combined with taurine (Tau) show more inhibitory effects in melanocytes than
the treatment of AZ alone. AZ combined with Tau inhibited the melanin production and tyrosinase activity of
B16F10 melanoma cells without significant cytotoxicity. Also inhibitory effects after treatment with these combined
chemical are stronger than AZ alone on melanogenesis.
Conclusions: These findings indicate that AZ with Tau might play an important role in the regulation of melanin
formation and be useful as effective ingredients in antimelanogesis.
Introduction
Melanin in human skin plays as a natural solar filter
absorbing and reflecting most of the UV radiation pas-
sing through the layer. Increased production and accu-
mulation of melanins describe a number of
hyperpigmentary disorders such as melasma and post-
inflammatory hyperpigmentation (PIH) [1]. These
hyperpigmentation can cause psychological and emo-
tional concern. Recently, many efforts have been
devoted to screening antimelanogenesis agents [2].
Antimelanogenesis can be achieved by controlling (i)
the activity of tyrosinase, tyrosinase gene expression,
tyrosinase related protein-1 (TRP-1) and tyrosinase
related protein-2 (TRP-2); (ii) melanin and melano-
some degradation and transfer to keratinocytes [3].
Recent studies suggested that another transcription
factor, MITF (microphthalmia transcription factor)
appear to play a regulatory role in early embryonic
development of the pigment systems [4-6]. However,
tyrosinase is the key role enzyme in melanin biosynth-
esis. Therefore, most of antimelanogenesis agents func-
tion specifically to reduce activity of this enzyme [7].
Azelaic acid (AZ) is a naturally occurring nonphenolic,
saturated, nine-carbon dicarboxylic acid compound iso-
lated from cultures Pityrosporum ovale. Initially, AZ was
developed for treatment of topical acne. However,
because of its inhibitory effect on tyrosinase, it has also
been used to treat melasma and PIH [8]. In vitro studies
show that AZ interferes with DNA synthesis and mito-
chondrial enzymes in abnormal melanocytes but does
not affect normal melanocytes [2,8-11].
The aim of present study was to investigate the anti-
melanogenic activity of combination of AZ and antioxi-
dant, taurine (Tau) in B16F10 mouse melanoma cells.
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any medium, provided the original work is properly cited.Moreover, to get molecular insight into the inhibition of
melanogenesis by combination of Tau and AZ, we
investigated its effect on tyrosinase, TRP-1, TRP-2,
MITF and phosphate ERK protein expression.
Materials and methods
Materials
AZ was purchased from Sigma-Aldrich (St. Louis, MO,
USA). AZ was dissolved in dimethyl sulfoxide (DMSO)
and the maximum concentration of DMSO was 0.1%.
Dulbecco’s Modified Eagle Medium (DMEM), dulbecco’s
p h o s p h a t eb u f f e r e ds a l i n e( D P B S ) ,f e t a lb o v i n es e r u m
(FBS), penicillin-streptomycin, and trypsin-EDTA were
purchased from WelGENE (Daegu, South Korea).
Cell lines and cell culture
The mouse melanoma cell line, B16F10, was obtained
from Korean Cell Line Bank (KCLB, Seoul, South
Korea). The cells were maintained in DMEM supple-
mented with 10% fetal bovine serum (FBS) and penicil-
lin-streptomycin. Cultures were routinely maintained at
37°C in a humidified atmosphere of 5% CO2.
Determination of cytotoxicity
The effect of drugs on the proliferation rate/cytotoxicity
of cancer cells was assessed by using a colorimetric
MTT assay. Briefly, cells were grown in 96-well flat-bot-
tomed plates in media with 10% FBS allowed attach
overnight. Then media was removed and replaced with
fresh media with various concentrations of drugs. At the
end of the treatment, medium was replaced by MTT
(2.5 mg/mL) solution and cells were incubated at 37°C.
Following 4 hr of incubation, MTT solution was dis-
carded formazan crystal was solubilized with DMSO.
The optical densities were measured at 570 nm. Results
were calculated as percentage of unexposed control.
Measurement of melanin contents
B16F10 melanoma cells were seeded at a density of
2.5×10
5 cells/60 mm culture dish. The cells were treated
with AZ combined with Tau for 24 hr. The cells pellets
were dissolved in 1 N NaOH at 60°C for 1 hr. The rela-
tive melanin content was determined by measuring the
absorbance at 475 nm in ELISA reader.
Tyrosinase activity assay
The tyrosinase activity was evaluated by measuring
the rated of dopachrome formation of L-DOPA (L-3,
4-dihydroxyphenylalanine). After incubation of AZ
with Tau for 24 hr, the cells were washed in ice-cold
PBS twice and lysed in phosphate buffer (0.1 M, pH
6.8) containing 1% (w/v) Triton X-100. The cellular
extract was clarified by centrifuged at 14000 rpm for
20 min.
Western blot analysis
After treatment with drugs, cells were washed with pho-
phate-buffered saline, harvested, and were lysed in RIPA
buffer [50 mM Tris-HCl (pH 8.0) with 150 mM NaCl,
1.0% nonidet P-40, 0.5% sodium deoxycholate, and 0.1%
sodium dodecyl sulfate] containing protease inhibitor
and phosphatase inhibitor (Roche, Indianapolis, IN,
USA). After centrifugation, the supernatant was sepa-
rated and stored at -70 C until use. Protein concentra-
tion was quantified by using a protein assay kit
(Bio-Rad, Hercules, CA). Equal amount of protein were
subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred to a polyvinylidene
difluoride membrane. The membrane was blocked and
incubated with primary antibody overnight in Tris-buf-
fered saline with 0.2% Tween-20 and 2.5% nonfat dry
milk (or 2.5% bovine serum albumin). The primary anti-
bodies used in the study are as follows: ERK 1/2 and
phospho-ERK 1/2 antibodies were purchased from Cell
signaling (Danvers, MA, USA) and were used at a
1:1000 dilution. Phospho-ERK1/2 antibody detects endo-
genous levels of ERK 1/2 when phosphorylated Thr/Tyr
of ERK1/2. TRP1, TRP2, tyrosinase and MITF antibo-
dies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) and used at a 1:500 dilution.
Following three washes of 10 minutes with Tris-buffered
saline with 0.2% Tween-20, blots were incubated with
horseradish peroxidase-conjugated secondary antibody
(Santa Cruz, CA, USA). The blots were washed again
three times in Tris-buffered saline with 0.2% Tween-20
and visualized with an ECL advance detection system.
Statistical analysis
All experiments were done at least 3 independent times
and values were expressed as means ± S.D. Significant
differences between groups were analyzed by using Stu-
dent t-test. A P-value of < 0.05 was considered statisti-
cally significant.
Results and discussion
Effects of combination of Tau and AZ on viability
Initially, the overall cytotoxic effect of combination of
Tau and AZ in mouse melanoma cells was assessed by
MTT assay. There were no growth inhibition effects of
Tau 20 mM and showed slight growth inhibition effects
at AZ 20 mM treatment (21.4%), and combination of
Tau 20 mM and AZ 20 mM (27%) for 24 hr (Fig. 1). In
further assessment, we used these concentrations.
Inhibitory action of tyrosinase and melanin contents of
B16F10 cells by combination of Tau and AZ
The antimelanogenesis can be helpful not only for cos-
metic as whitening purposes but also for the treatment
of abnormal pigmentation. Recently, tyrosinase inhibitor
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its potential to inhibit dermal melanin formation [12].
We investigated the inhibitory effect of combination of
Tau and AZ on tyrosinase activity. As Fig. 2A indicates,
AZ and Tau exhibit inhibition of tyrosinase activity.
Especially, incubation with combination of Tau and AZ,
tyrosinase activities were suppressed, showing 41% com-
pare with control. To establish the relative efficacy of
combination of Tau and AZ, we also compared with a
well known antimelanogenic agents, kojic acid on tyrosi-
nase activity. The inhibitory effect of combination of
Tau and AZ was significantly less than to kojic acid. It
has been known that melanin synthesis can be activated
by a-melanocyte-stimulating hormone (a-MSH) and
LPS [13,14]. In our study, we used a-MSH and LPS as
melanogenic inducers. B16F10 cells were incubated in
t h ep r e s e n c eo f1 0 0n Mo fa-MSH or 1 μg/ml of LPS
and then treated for 24 hr with each drug. As shown in
Fig 2B and 2C, Tau, AZ and combination of Tau and
AZ effectively inhibited tyrosinase activities as compared
to the a-MSH or LPS treated groups.
To get evidence on the involvement of combination of
Tau and AZ in melanogenesis, we analyzed the inhibi-
tion of melanin production in B16F10 cells. As exhibited
in Fig. 3A, treatments with Tau, AZ and combination
Tau and AZ, the melanin contents were decreased: 24 %
of Tau, 37% of AZ, 49% of combination of Tau and AZ
compared to control. We also examined inhibitory
effects of melanin contents in a-MSH or LPS -induced
B16F10 melanoma cells. Results showed that melanin
synthesis was effectively inhibited in a-MSH or LPS-
induced B16F10 melanoma cells (Fig. 3B and 3C). These
results indicated that combination of Tau and AZ
exhibited more powerful inhibitory effects on tyrosinase
activity and melanin production compared to single
treatment of Tau or AZ.
Effects of combination of Tau and AZ on the expression
of tyrosinase, TRP -1 and TRP-2
The tyrosinase gene family including tyrosinase, TRP-1
and TRP-2 has been determined to play an important
role in the regulation of melanogenesis [15]. Next, to
know the effects of combination of Tau and AZ on tyro-
sinase or other melanogenic enzyme like a TRP-1 and
TRP-2 expression, western blot analysis was performed
Figure 1 Cell viability of Tau and AZ. Cell viability of Tau and AZ
was analyzed using the MTT assay. Cells were incubated with Tau
(taurine 20 mM), AZ (azelaic acid 20 mM) and combination of Tau
and AZ. Viability was calculated as the percent of control. The bars
represent the mean values ± SD of triplicate.
***P < 0.001 versus
control values.
Figure 2 Inhibitory effect of combination of Tau and AZ on
tyrosinase enzyme activity. (A) After incubation with Tau (20
mM), AZ (20 mM) or combination of Tau and AZ, tyrosinase activity
was subsequently measured as described in the Material and
Methods. B16F10 cells were incubated in the presence of (B) 100
nM of a-MSH or (C) 1 μg/ml of LPS and then treated for 24 hr with
each drug. Tyrosinase activity was expressed as % of control. Results
are the means of three independent experiments. The bars
represent the mean values ± SD of triplicate.
**P< 0.01;
***P < 0.001
versus control values.
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TRP-1, TRP-2 expression with single treatment of Tau
or AZ and combination of Tau and AZ compared with
control (Fig. 4). From the western blot analysis, reduce
of melanin contents and tyrosianse activity were asso-
ciated with attenuated amount of tyrosinase, TRP1 and
TRP2 protein levels.
Effects of combination of Tau and AZ on MITF expression
To gain further molecular insight into the inhibition of
melanogenesis, we investigate the effects on ERK 1/2
and melanocyte-specific transcription factor (MITF)
molecules by combination of Tau and AZ.
MITF is one of the pivotal transcriptional regulators
and is associated with the pigmentation, proliferation
and survival of melanocytes [16]. MITF effectively trans-
activates the expression of tyrosinase and its related
genes by binding to their common promoters [17]. We
examined the MITF expression after single treatment of
Tau or AZ and combination of Tau and AZ by western
blot. As shown in Fig. 5, there was reduction of MITF
level by single treatment of Tau or AZ, and reduction of
treatment of combination of Tau and AZ was especially
dramatic.
Several studies have reported that ERK is an impor-
tant regulator of melanogenesis because ERK activation
Figure 3 Melanin contents in B16F10 cells. (A) After incubation
with Tau (20 mM), AZ (20 mM) or combination of Tau and AZ,
melanin content was subsequently measured as described in the
Material and Methods. B16F10 cells were incubated in the presence
of (B) 100 nM of a-MSH or (C) 1 μg/ml of LPS and then treated for
24 hr with each drug. Total melanin content was expressed as % of
control. Results are the means of three independent experiments.
The bars represent the mean values ± SD of triplicate.
**P< 0.01;
***P < 0.001 versus control values.
Figure 4 Inhibitory effect of combination of Tau and AZ on
tyrosinase, TRP1 and TRP2. Cells were treated with each drug.
Cell lystates were examined by western blotting analysis using TRP1,
TRP2 and tyrosinase antibodies.
Figure 5 Effect of combination of Tau and AZ on activation of
ERK and MITF protein. Cells were treated with each drug. Cell
lystates were examined by western blotting analysis using total and
phospho ERK and MITF antibodies.
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ubiquitination and degradation [18,19]. To investigate
the effects of combination of Tau and AZ on ERK acti-
vation, western blot analysis was carried out. Combina-
tion of Tau and AZ stimulated the phosphorylation of
ERK (Fig. 5). These results indicated that antimelano-
genic activity of combination of Tau and AZ was asso-
ciated with suppression of MITF and activation of ERK
phosphorylation.
Conclusions
In summary, we have demonstrated that combination of
Tau and AZ inhibited melanin production and tyrosi-
nase activity. Western blotting data indicated that the
antimelanogenic activity of treatment with combination
of Tau and AZ is probably due to suppression of tyrosi-
nase, TRP1, TRP2 and MITF and increase of ERK acti-
vation in B16F10 mouse melanoma cells. Thus, our data
suggested that combination of Tau and AZ may poten-
tially be used in development of depigmenting agents.
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